NantHealth Added to Nasdaq Biotech Index

CULVER CITY, Calif.--(BUSINESS WIRE)-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it has been selected by NASDAQ for inclusion in the NASDAQ Biotechnology Index® (NASDAQ: NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective at market open on Monday, December 19, 2016.

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

“We are pleased with the addition of NantHealth to the NBI,” said Patrick Soon-Shiong, M.D., chief executive officer and chairman of NantHealth. “Inclusion in the NBI will enable exposure of NantHealth to a broader range of investors.”

About NantHealth

NantHealth is a transformational healthcare IT company converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care, in the time of need, anywhere, anytime. NantHealth works to transform clinical delivery with actionable clinical intelligence at the moment of decision, enabling clinical discovery through real-time machine learning systems. The company’s technology empowers physicians, patients, payers and researchers to transcend genomics into the world of proteomics and the traditional barriers of today’s healthcare system. By converging molecular science, computer science and big data technology, the Nant Service Oriented Operating System (NantOS) platform empowers physicians, patients and payers to coordinate best care, monitor outcomes and control cost in real time. This is the first operating system of its kind in healthcare that is based on supply chain principles and grid service oriented architecture and integrates the knowledge base with the delivery system and the payment system, enabling 21st century coordinated care at a lower cost. For more information, please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @solvehealthcare.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161213005523/en/

for NantHealth
Investor Contact:
Robert Jaffe, 424-288-4098
[email protected]

Source: NantHealth

You May Also Be Interested In

• 49NORTH RELEASES GLOBAL PROCEDURE DESIGNER, A PROVEN INSTRUMENT FLIGHT PROCEDURE DESIGN SOLUTION REFRESHED FOR COMPLIANCE WITH LATEST REGULATIONS
• After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
• XRP Investors Are Selling at a Loss, According to On-Chain Data